US Congress Senate Bill 2030 (Prior Session Legislation)

---

Spectrum: Slight Partisan Bill (Republican 4-2)
Status: Introduced on September 15 2015 - 25% progression, died in chamber
Action: 2016-04-05 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 416.
Text: Latest bill text (Introduced) [PDF]

Advancing Targeted Therapies for Rare Diseases Act of 2016 (Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to permit the Food and Drug Administration to allow the sponsor of a new drug or biological product for the treatment of a rare, serious condition to rely upon information submitted for an approved medication that uses the same technology. For a sponsor to be eligible to rely upon submitted information: (1) the sponsor must have developed, or have a right of reference to, the relied upon information; and (2) the new medication must use nucleic acids (e.g., DNA) or similar chemicals, or must affect a disease-causing product of a mutated gene (e.g., the protein that causes cystic fibrosis).

Advancing Targeted Therapies for Rare Diseases Act of 2016

Sen. Michael Bennet [D-CO]	Sen. Richard Burr [R-NC]	Sen. Elizabeth Warren [D-MA]	Sen. Orrin Hatch [R-UT]
Sen. Michael Enzi [R-WY]	Sen. Marco Rubio [R-FL]

Date	Chamber	Action
2016-04-05	Senate	Placed on Senate Legislative Calendar under General Orders. Calendar No. 416.
2016-04-05	Senate	Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.
2016-02-09	Senate	Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
2015-09-15	Senate	Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Type	Source
Summary	https://www.congress.gov/bill/114th-congress/senate-bill/2030/all-info
Text	https://www.congress.gov/114/bills/s2030/BILLS-114s2030is.pdf
Text	https://www.congress.gov/114/bills/s2030/BILLS-114s2030rs.pdf